Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending

   Analysis In Health Economics Review Concludes Effective Medical Obesity
                   Treatment Could Reduce Medicare Spending


PR Newswire

MOUNTAIN VIEW, Calif., March 25, 2013

MOUNTAIN VIEW, Calif., March 25, 2013 /PRNewswire/ --VIVUS, Inc. (Nasdaq:
VVUS) announced today that a new study demonstrates that effective medical
treatment providing 10% to 15% weight loss could lead to significant
improvements in Medicare spending by reversing or reducing significant health
consequences such as type 2 diabetes, hypertension and dyslipidemia in obese
or overweight patients.

The study, conducted by Kenneth E. Thorpe, PhD, Professor and Chair,
Department of Health Policy and Management, Rollins School of Public Health,
Emory University, was published today online
[] in Health
Economics Review. It is the first research to project the potential impact
that a new generation of FDA-approved anti-obesity medications could have on
Medicare spending among adults aged 65 and older who are either obese or
overweight with at least one weight-related comorbidity such as hypertension
or diabetes.

"America's weight problem is contributing to its spending problem," said Dr.
Thorpe. "Including anti-obesity medications that can achieve this level of
efficacy in the Medicare benefits package will fill the gap between lifestyle
changes alone and bariatric surgery. It could save billions in lifetime
Medicare spending."

"Obesity is a chronic condition that contributes to a number of comorbidities
such as diabetes and hypertension, which are costly to treat," said W. Timothy
Garvey, MD, Butterworth Professor and Chair, Department of Nutrition Sciences
at the University of Alabama at Birmingham. "By targeting obesity as a key
contributor to these conditions, we can improve patient outcomes and make a
positive impact on the costs related to treating these comorbidities."

The study suggests that 10% to 15% weight loss in obese and overweight people
could produce gross per capita savings ranging from approximately $6,000 to
$13,000 over a 10-year period, depending on a variety of factors. Potential
savings were even greater over a lifetime.Collectively, among the estimated
11.2 million Medicare patients who are obese or overweight with at least one
weight-related comorbidity, the lifetime savings could total in the billions
of dollars.

The study highlighted that weight loss produced by Qsymia^® (phentermine and
topiramate extended-release) capsules CIV demonstrated durability over a
two-year period of treatment.The Qsymia mid and top dose led to greater
weight loss results, and patients who adhere to a treatment regimen are more
likely to achieve 10% to 15% weight loss and sustain it over time.

About Qsymia
Qsymia is approved in the U.S. and is indicated as an adjunct to a
reduced-calorie diet and increased physical activity for chronic weight
management in adults with an initial body mass index (BMI) of 30 kg/m^2 or
greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at
least one weight-related medical condition such as high blood pressure, type 2
diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
Qsymia is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea. For more information about the company,
please visit

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, our limited commercial experience
with Qsymia in the U.S.; the timing of initiation and completion of the
clinical studies required as part of the approval of Qsymia by the United
States Food and Drug Administration, or FDA; the response from the FDA to the
data that VIVUS will submit relating to post-approval clinical studies; the
impact of the indicated uses and contraindications contained in the Qsymia
label and the Risk Evaluation and Mitigation Strategy, or REMS, requirements;
the impact of distribution of Qsymia through a certified home delivery
pharmacy network; whether or not the FDA approves our amendment to the REMS
for Qsymia, which, if approved, would allow dispensing through select
certified retail pharmacies to increase access while meeting all requirements
of the REMS; that we may be required to provide further analysis of previously
submitted clinical trial data; the negative opinion of the European Medicines
Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, for
the Marketing Authorization Application, or MAA, for Qsymia; our ability to
successfully commercialize or establish a marketing partnership for avanafil,
which will be marketed in the U.S. under the name STENDRA™; the ability of our
partners to obtain and maintain regulatory approvals to manufacture and
adequately supply our products to meet demand; our history of losses and
variable quarterly results; substantial competition; risks related to the
failure to protect our intellectual property and litigation in which we may
become involved; uncertainties of government or third party payer
reimbursement; our reliance on sole source suppliers; our limited sales and
marketing and manufacturing experience; our reliance on third parties and our
collaborative partners; our failure to continue to develop innovative
investigational drug candidates and drugs; risks related to the failure to
obtain FDA or foreign authority clearances or approvals and noncompliance with
FDA or foreign authority regulations; our ability to demonstrate through
clinical testing the safety and effectiveness of our investigational drug
candidates; the timing of initiation and completion of clinical trials and
submissions to foreign authorities; the results of post-marketing studies are
not favorable; compliance with post-marketing regulatory standards is not
maintained; the volatility and liquidity of the financial markets; our
liquidity and capital resources; and our expected future revenues, operations
and expenditures. As with any pharmaceutical in development, there are
significant risks in the development, the regulatory approval, and the
commercialization of new products. There are no guarantees that the product
will receive regulatory approval outside the United States for any indication
or prove to be commercially successful. VIVUS does not undertake an obligation
to update or revise any forward-looking statements. Investors should read the
risk factors set forth in VIVUS's Form 10-K for the year ending December 31,
2012, and periodic reports filed with the Securities and Exchange Commission.


Contact: VIVUS, Inc., Timothy E. Morris, Chief Financial Officer,; Media Relations: GolinHarris, Ashley Buford,, (212) 373-6045; Investor Relations: The Trout Group,
Brian Korb,, 646-378-2923
Press spacebar to pause and continue. Press esc to stop.